No abstract

Synaptic damage is one of the most prevalent pathophysiological responses to traumatic CNS injury and underlies much of the associated cognitive dysfunction; however, it is poorly understood. The D‐amino acid, D‐serine, serves as the primary co‐agonist at synaptic NMDA receptors (NDMARs) and is a critical mediator of NMDAR‐dependent transmission and synaptic plasticity. In physiological conditions, D‐serine is produced and released by neurons from the enzymatic conversion of L‐serine by serine racemase (SRR). However, under inflammatory conditions, glial cells become a major source of D‐serine. Here, we report that D‐serine synthesized by reactive glia plays a critical role in synaptic damage after traumatic brain injury (TBI) and identify the therapeutic potential of inhibiting glial D‐serine release though the transporter Slc1a4 (ASCT1). Furthermore, using cell‐specific genetic strategies and pharmacology, we demonstrate that TBI‐induced synaptic damage and memory impairment requires D‐serine synthesis and release from both reactive astrocytes and microglia. Analysis of the murine cortex and acutely resected human TBI brain also show increased SRR and Slc1a4 levels. Together, these findings support a novel role for glial D‐serine in acute pathological dysfunction following brain trauma, whereby these reactive cells provide the excess co‐agonist levels necessary to initiate NMDAR‐mediated synaptic damage.

Clincal trials examining neuroprotective strategies after brain injury, including those targeting cell death mechanisms, have been underwhelming. This may be in part due to an incomplete understanding of the signaling mechanisms that induce cell death after traumatic brain injury. The recent identification of a new family of death receptors that initiate pro-cell death signals in the absence of their ligand, called dependence receptors, provides new insight into the factors that contribute to brain injury. Here, we show that blocking the dependence receptor signaling of EphB3 improves oligodendrocyte cell survival in a murine controlled cortical impact injury model, which leads to improved myelin sparing, axonal conductance and behavioral recovery. EphB3 also functions as a cysteine-aspartic protease substrate, where the recruitment of injury-dependent adaptor protein Dral/FHL-2 together with capsase-8 or -9 lead to EphB3 cleavage to initiate cell death signals in murine and human traumatic brain injured patients, supporting a conserved mechanism of cell death. These pro-apoptotic responses can be blocked via exogenous ephrinB3 ligand administration leading to improved oligodendrocyte survival. In short, our findings identify a novel mechanims of oligodendrocyte cell death in the traumatically injured brain that may reflect an important neuroprotective strategy in patients.